tickrz reports
tickrz rank
D
AbbVie Inc (ABBV)
Healthcare | Drugs
86.29  0.94%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 346Warren Buffett RankC / 347
Pure Value RankD / 386Dividend RankC / 228
Moat RankB / 121Financial Strength RankC / 239
Growth RankC / 257Momentum RankC / 274
ABBV vs DRUGS SECTOR & S&P 500
VALUATION
ABBVSECTORS&P 500
P/E RATIO21.1335.719.28
EV/EBITDA RATIO16.2125.111.77
P/S RATIO5.237.12.03
P/B RATIO23.268.73.09
QUALITY
RETURN ON EQUITY113.57%16.98%13.82%
RETURN ON CAPITAL18.2%26.23%10.04%
NET MARGIN23.1%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.85%
PAYOUT RATIO59.21%
3 YR DIVIDEND GROWTH13.67%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY761%
INTEREST COVERAGE9.72x
CURRENT RATIO1.38
GROWTH
5 YR EPS GROWTH10.82%
5 YR SPS GROWTH8.01%
5 YR BPS GROWTH-17.75%
About tickrz
Key Concepts
Great Investors
tickrz Report
tickrz rank D / 346
AbbVie Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 386Warren Buffett ranking C / 347
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. AbbVie Inc's valuation score is comprised of a P/E ratio of 21.1x, a P/B ratio of 23.3x, a P/S ratio of 5.2x, and an EV/EBITDA ratio of 16.2x. AbbVie Inc ranks 386 out of the S&P 500 constituents on valuation--a relatively weak score.AbbVie Inc ranks 347 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, AbbVie Inc is probably not for you.

quality
moat B / 121financial strength C / 239
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.AbbVie Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 9.72x, a debt/equity ratio of 761% and a Moat Rank of 121 translate to a weak Financial Strength score.


momentum C / 274
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 11.03% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 274. Based on its 12 month stock performance, AbbVie Inc will not appeal to momentum investors.

yield C / 228
value + yield
Shares currently yield 2.85%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, AbbVie Inc ranks 228 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth C / 257
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 10.8% 5 year annualized EPS growth, 8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -17.7% speak to its relatively poor ranking.

AbbVie Inc (ABBV)
Healthcare | Drugs
86.29  0.94%


tickrz rank
D
VALUATION RATIOS
P/E Ratio21.13x
P/B Ratio23.26x
P/S Ratio5.23x
EV/EBITDA Ratio16.21x
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.85%
PAYOUT RATIO59.21%
3 YR DIVIDEND GROWTH13.67%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY761%
INTEREST COVERAGE9.72x
CURRENT RATIO1.38
MOAT
ROE113.57%
ROIC18.2%
Net Margin23.1%
GROWTH
5 YR EPS GROWTH10.82%
5 YR SPS GROWTH8.01%
5 YR BPS GROWTH-17.75%

TICKRZ RANK
AbbVie Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. AbbVie Inc's valuation score is comprised of a P/E ratio of 21.1x, a P/B ratio of 23.3x, a P/S ratio of 5.2x, and an EV/EBITDA ratio of 16.2x. AbbVie Inc ranks 386 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
AbbVie Inc ranks 347 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, AbbVie Inc is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.

FINANCIAL STRENGTH
AbbVie Inc has a Piotroski F Score of 5 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 9.72x, a debt/equity ratio of 761% and a Moat Rank of 121 translate to a weak Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 11.03% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 274. Based on its 12 month stock performance, AbbVie Inc will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.85%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, AbbVie Inc ranks 228 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 10.8% 5 year annualized EPS growth, 8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -17.7% speak to its relatively poor ranking.